Can Dingtai Pharmaceutical Research Resolve Its HK$2.7 Billion Redemption Dilemma?

ZC Asia has learnt that Jiangsu Dingtai Pharmaceutical Research (Group) Co., Ltd. (hereinafter referred to as ‘Dingtai Pharmaceutical Research’) has formally submitted its application for a Main Board listing to the Hong Kong Stock Exchange, with Citigroup and Haitong International acting as joint sponsors.

Experimental monkeys form core competitiveness, with resource barriers and pricing risks coexisting

Established in 2008, Dingtai Pharmaceutical Research was initially co-founded by Nanjing property developer Chen Maolin and the Jiangsu Provincial Institute of Pharmaceutical Research. Following subsequent equity restructuring, current Chairman Zhang Xuefeng took charge in 2021 and introduced several prominent investment institutions. The company's core business encompasses non-clinical safety, efficacy, and pharmacokinetic (DMPK) studies alongside clinical trial services, forming an integrated pipeline from drug screening to critical validation.

Its most distinctive competitive advantage lies in non-human primate (NHP) resources. Experimental monkeys, owing to their high physiological similarity to humans, serve as irreplaceable models in drug safety evaluation. According to disclosures, Dingtai holds over 20,000 experimental monkeys, ranking third in scale domestically behind WuXi AppTec and Zhaoyan New Drug. Within the non-clinical research sector for cardiovascular and metabolic diseases in 2024, the company achieved the highest revenue.

However, the volatile pricing of experimental monkeys has become a critical variable affecting the company's profit stability. Between 2021 and 2022, the unit price surged from RMB 70,000 to RMB 148,000. It subsequently declined to RMB 84,900 in 2024 before rebounding to approximately RMB 100,000 in 2025. These price fluctuations caused frequent changes in the fair value of the company's biological assets. While this resulted in a gain of RMB 136 million in the first half of 2025, excluding this factor, the core business was only marginally profitable.

Revenue shows steady growth, yet profits remain negative for two consecutive years

Financial data indicates that from 2022 to 2024, Dingtai Pharmaceutical Research recorded revenues of RMB 725 million, RMB 767 million, and RMB 713 million respectively. During the same period, net profits stood at RMB 143 million, -RMB 51.946 million, and -RMB 252 million, marking losses for two consecutive years. In the first half of 2025, revenue grew 21.41% year-on-year to RMB 377 million, with a profit of RMB 64.712 million. The gross profit margin rebounded from 32.54% in the same period last year to 38.9%, though it remains below the 2022 peak of 48.44%.

The margin decline primarily stemmed from the increasing proportion of low-margin clinical trial services revenue, rising from 10.9% in 2022 to 23.9% in the first half of 2025. The company's strategic expansion into clinical services since 2021, while diversifying its revenue structure, has also intensified profitability pressures.

Liquidity crisis looms with redemption liabilities reaching RMB 2.7 billion

Despite signs of business recovery, Dingtai Pharmaceutical Research's financial position remains concerning. As of 30 June 2025, the company held current assets of RMB 1.578 billion against current liabilities of RMB 3.534 billion, revealing a liquidity shortfall nearing RMB 2 billion and indicating a state of negative net worth.

The most pressing pressure stems from redemption liabilities. In six financing rounds completed since 2021, the company issued preferred shares stipulating that investors may demand redemption at the issue price plus 10% annual interest if a ‘qualified listing’ is not achieved within a specified period. By end-June 2025, these liabilities reached RMB 2.727 billion, while the company held only RMB 419 million in cash and equivalents – covering less than 16% of the obligation.

Regarding cash flow, apart from recording a net operating cash inflow of RMB 254 million in 2022, the company has experienced a cumulative net outflow of RMB 479 million since the start of 2023. Should the listing process encounter obstacles or valuations fall short of expectations, the company will face severe liquidity challenges.

Industry Polarisation Intensifies: CRO Sector Experiences ‘Heaven and Hell’

The CRO industry is currently undergoing significant differentiation. In the first half of 2025, Kanglong Chemical achieved revenue of RMB 6.441 billion, representing a year-on-year increase of 14.9%. Conversely, Tigermed saw its revenue decline by 3.21% year-on-year, with non-recurring adjusted net profit attributable to shareholders falling by 67.09%. The sector as a whole faces challenges including intensified competition, profit dilution, and extended payment cycles.

Dingtai Pharmaceutical Research operates at a significantly smaller scale than leading firms. In the first half of 2025, its revenue stood at merely RMB 377 million, compared to RMB 6.441 billion, RMB 3.25 billion, and RMB 669 million for Kanglong Chemical, Tigermed, and Zhaoyan New Drug respectively. Within an increasingly competitive market, small-to-medium CRO enterprises find themselves at a disadvantage in terms of pricing power, payment collection, and client retention.

Overseas expansion yields results, with IPO success hinging on capital chain

To counter domestic market competition, Dingtai Pharmaceutical Research accelerated its international expansion. In the first half of 2025, overseas revenue surged from 13.3% in 2023 to 30.2%, indicating initial success in building its international sales network. The company has provided non-clinical research services to over 700 clients worldwide, cumulatively assisting them in securing more than 200 approvals from the National Medical Products Administration (NMPA) and over 40 approvals from overseas regulatory bodies.

However, the company still faces goodwill impairment risks. The integration of previously acquired Dingyue Bio and Jiangsu Yadong has yielded less-than-expected results, leading to a goodwill impairment charge of RMB 66 million in 2022. As of the end of June 2025, the carrying value of goodwill remains at RMB 88 million. Should future operations fall short of expectations, further impairment charges may be required.

Against the backdrop of a broader valuation correction within the CRO sector, whether Dingtai Pharmaceutical Research can successfully list by leveraging its experimental monkey resources and disease modelling capabilities, thereby alleviating funding pressures, remains subject to market validation. This IPO represents not only a pivotal step in broadening its financing channels but also a comprehensive assessment of its business model and financial structure.

Disclaimer: The content herein is for reference only and does not constitute any form of investment advice. Should any information contained herein prove inaccurate, incomplete, or potentially misleading, please refer to the company's official announcements. Market risks exist; investment requires caution.